Technologies
Kairos Pharma Technologies To Innovate & Overcome
Kairos Pharma is committed to transforming the landscape of cancer treatment by addressing critical gaps left by conventional therapies. Our cutting-edge technologies focus on creating innovative solutions for cancers that are resistant to existing treatments. Kairos Pharma is bridging the divide between unmet medical needs and accessible, effective therapies, offering renewed hope to patients worldwide.
Explore our innovative technologies driving the future of cancer treatment breakthroughs.
Technologies
UNMET MEDICAL NEED
DRUG
HOW KAIROS ADDRESSES UNMET MEDICAL NEED
Development of resistance to many, otherwise effective cancer drugs
ENV 105
• ENV 105 inhibits CD105 (CD105 is the protein responsible for cancer drug resistance in various forms of cancer)
• Currently in Phase 2 trial in prostate cancer and Phase 1 trial in lung cancer
T cells drastically reduced by cancer
KROS 101
• KROS 101 uses a novel dual mechanism to increase killer T effector cells and reduce suppressor T reg cells (T cells have 2 types cells: those that kill cancer cells and those that inhibit the killer T cell response)
KROS 102
Immunosuppression from cancer
KROS 201
• KROS 201 are killer T effector cells generated outside of the immunosuppressed body which will be delivered to cancer cells to kill cancer stem cells that drive cancer growth.
• Currently cleared for IND (investigational new drug application) by FDA
Chemotherapies are untargeted and immunosuppressive
KROS 301
• KROS 301 kills tumor cells while leaving normal cells unscathed by targeting the NF-kB molecular pathway. KROS 301 also inhibits the mechanism of PD-L1 expression on tumor cells (PD-L1 is a “checkpoint inhibitor” that prevents T cells from killing the cancer)
Tumor environment is immunosuppressive from macrophages (a type of white cell that can be either anti-cancer or pro-cancer)
KROS 401
• KROS 401 targets pro-cancer macrophages to convert them into anti-cancer macrophages
Development of resistance to various specific chemotherapies
ENV 205
• ENV 205 targets & expels mitochondrial DNA that are released by tumors which use this mechanism of resistance against specific chemotherapies
Related links
Pipeline
Explore our drug development pipeline, showcasing innovative therapies and cutting-edge technologies aimed at addressing unmet medical needs and transforming patient outcomes.
Intellectual Property
Discover our robust intellectual property portfolio, protecting groundbreaking innovations and ensuring the advancement of transformative therapies for cancer and beyond.
Investors
Access key investor information, financial updates, strategic plans, and insights into our mission to drive innovation and deliver transformative therapies in cancer research and treatment.
Technologies
Kairos Pharma Technologies
To Innovate & Overcome
Kairos Pharma is committed to transforming the landscape of cancer treatment by addressing critical gaps left by conventional therapies. Our cutting-edge technologies focus on creating innovative solutions for cancers that are resistant to existing treatments. Kairos Pharma is bridging the divide between unmet medical needs and accessible, effective therapies, offering renewed hope to patients worldwide.
Explore our innovative technologies driving the future of cancer treatment breakthroughs.
Technologies
UNMET MEDICAL NEED
DRUG
HOW KAIROS ADDRESSES UNMET MEDICAL NEED
Development of resistance to many, otherwise effective cancer drugs
ENV 105
• ENV 105 inhibits CD105 (CD105 is the protein responsible for cancer drug resistance in various forms of cancer)
• Currently in Phase 2 trial in prostate cancer and Phase 1 trial in lung cancer
T cells drastically reduced by cancer
KROS 101
• KROS 101 uses a novel dual mechanism to increase killer T effector cells and reduce suppressor T reg cells (T cells have 2 types cells: those that kill cancer cells and those that inhibit the killer T cell response)
KROS 102
Immunosuppression from cancer
KROS 201
• KROS 201 are killer T effector cells generated outside of the immunosuppressed body which will be delivered to cancer cells to kill cancer stem cells that drive cancer growth.
• Currently cleared for IND (investigational new drug application) by FDA
Chemotherapies are untargeted and immunosuppressive
KROS 301
• KROS 301 kills tumor cells while leaving normal cells unscathed by targeting the NF-kB molecular pathway. KROS 301 also inhibits the mechanism of PD-L1 expression on tumor cells (PD-L1 is a “checkpoint inhibitor” that prevents T cells from killing the cancer)
Tumor environment is immunosuppressive from macrophages (a type of white cell that can be either anti-cancer or pro-cancer)
KROS 401
• KROS 401 targets pro-cancer macrophages to convert them into anti-cancer macrophages
Development of resistance to various specific chemotherapies
ENV 205
• ENV 205 targets & expels mitochondrial DNA that are released by tumors which use this mechanism of resistance against specific chemotherapies
Related links
Pipeline
Explore our drug development pipeline, showcasing innovative therapies and cutting-edge technologies aimed at addressing unmet medical needs and transforming patient outcomes.
Intellectual Property
Discover our robust intellectual property portfolio, protecting groundbreaking innovations and ensuring the advancement of transformative therapies for cancer and beyond.
Investors
Access key investor information, financial updates, strategic plans, and insights into our mission to drive innovation and deliver transformative therapies in cancer research and treatment.
Technologies
Kairos Pharma is committed to transforming the landscape of cancer treatment by addressing critical gaps left by conventional therapies. Our cutting-edge technologies focus on creating innovative solutions for cancers that are resistant to existing treatments. Kairos Pharma is bridging the divide between unmet medical needs and accessible, effective therapies, offering renewed hope to patients worldwide.
Explore our innovative technologies driving the future of cancer treatment breakthroughs.
Technologies
Drug: ENV 105
UNMET MEDICAL NEED
Development of resistance to many, otherwise effective cancer drugs
HOW KAIROS ADDRESSES UNMET MEDICAL NEED
• ENV 105 inhibits CD105 (CD105 is the protein responsible for cancer drug resistance in various forms of cancer)
• Currently in Phase 2 trial in prostate cancer and Phase 1 trial in lung cancer
Drug: KROS 101
UNMET MEDICAL NEED
T cells drastically reduced by cancer
HOW KAIROS ADDRESSES UNMET MEDICAL NEED
• KROS 101 uses a novel dual mechanism to increase killer T effector cells and reduce suppressor T reg cells (T cells have 2 types cells: those that kill cancer cells and those that inhibit the killer T cell response)
Drug: KROS 102
UNMET MEDICAL NEED
In autoimmune diseases, T cells are overactive against normal cells
HOW KAIROS ADDRESSES UNMET MEDICAL NEED
• KROS 102 has the opposite effect of KROS101, by decreasing the number of overactive T effector cells and increasing T reg suppressor cells
Drug: KROS 201
UNMET MEDICAL NEED
Immunosuppression from cancer
HOW KAIROS ADDRESSES UNMET MEDICAL NEED
• KROS 201 are killer T effector cells generated outside of the immunosuppressed body which will be delivered to cancer cells to kill cancer stem cells that drive cancer growth.
• Currently cleared for IND (investigational new drug application) by FDA
Drug: KROS 301
UNMET MEDICAL NEED
Chemotherapies are untargeted and immunosuppressive
HOW KAIROS ADDRESSES UNMET MEDICAL NEED
• KROS 301 kills tumor cells while leaving normal cells unscathed by targeting the NF-kB molecular pathway. KROS 301 also inhibits the mechanism of PD-L1 expression on tumor cells (PD-L1 is a “checkpoint inhibitor” that prevents T cells from killing the cancer)
Drug: KROS 401
UNMET MEDICAL NEED
Tumor environment is immunosuppressive from macrophages (a type of white cell that can be either anti-cancer or pro-cancer)
HOW KAIROS ADDRESSES UNMET MEDICAL NEED
• KROS 401 targets pro-cancer macrophages to convert them into anti-cancer macrophages
Drug: ENV 205
UNMET MEDICAL NEED
Development of resistance to various specific chemotherapies
HOW KAIROS ADDRESSES UNMET MEDICAL NEED
• ENV 205 targets & expels mitochondrial DNA that are released by tumors which use this mechanism of resistance against specific chemotherapies
Related links
Pipeline
Intellectual Property
Discover our robust intellectual property portfolio, protecting groundbreaking innovations and ensuring the advancement of transformative therapies for cancer and beyond.
Investors
Access key investor information, financial updates, strategic plans, and insights into our mission to drive innovation and deliver transformative therapies in cancer research and treatment.
